The Fly | FRMM

Over a week ago

Forum Markets price target raised by $4 at Benchmark, here's why

FRMM

May 15, 7:48 AM

Forum Markets narrows 2026 revenue view to $18M-$22M from $18M-$26M

FRMM

May 14, 8:11 AM

Forum Markets reports Q1 EPS ($3.64) vs. ($5.54) last year

FRMM

May 14, 8:10 AM

Forum Markets initiated with bullish view at Clear Street, here's why

FRMM

May 11, 5:19 PM

Crypto Currents: Robinhood crypto revenue collapses 47% in Q1

+10

Apr 29, 11:29 AM

Forum Markets reinitiates share repurchase program, forms special committee

FRMM

Apr 17, 8:34 AM

Crypto Currents: Morgan Stanley's bitcoin ETF debut meets ceasefire rally

+15

Apr 8, 12:03 PM

Forum Markets initiated with a Speculative Buy at Benchmark

FRMM

Apr 7, 7:45 AM

Forum Markets initiated with a Speculative Buy at Benchmark

FRMM

Apr 7, 6:16 AM

Forum Markets appoints Robert Spake as General Counsel

FRMM

Mar 3, 9:02 AM

Notable open interest changes for March 3rd

Mar 3, 8:55 AM

Crypto Currents: Treasuries buy the dip as geopolitics weigh on flows

+12

Mar 2, 12:02 PM

Six new option listings and four option delistings on March 2nd

Mar 2, 8:30 AM

ETHZilla updates corporate name, brand to Forum Markets

Feb 25, 9:19 AM

No more stories

Pioneering Scientific Leadership: The company benefits from a founding team with a strong track record of groundbreaking discoveries in inflammation and anti-TNF biology, providing a robust scientific foundation for its pipeline.

Addressing High Unmet Medical Needs: 180 Life Sciences focuses on conditions like Dupuytren's contracture and frozen shoulder, which currently lack effective non-surgical treatments, presenting a significant market opportunity.

Leveraging Proven Biological Pathways: Their core strategy often involves applying the well-established and clinically validated anti-TNF mechanism of action to new indications, thereby reducing the inherent biological risk of drug development.

Clinical Trial Failure Risk: The company's lead product candidates are in early-stage clinical development, and there is a high risk that they will not demonstrate safety or efficacy, or complete trials successfully to obtain regulatory approval.

Regulatory Approval Risk: Even with positive clinical trial results, the company may fail to obtain necessary regulatory approvals from agencies like the FDA or EMA, which would prevent any product from reaching the market.

Capital Requirements and Dilution Risk: 180 Life Sciences will require substantial additional financing to fund its operations and clinical programs, which may lead to significant dilution for existing shareholders through equity offerings.